SciClone Pharmaceuticals Newswire

SciClone Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for SciClone Pharmaceuticals.

Results 1 - 20 of 51 in SciClone Pharmaceuticals

  1. Sidley Lands Life Sciences Licensing Pro From King & SpaldingRead the original story w/Photo

    Monday Oct 8 | American Lawyer

    ... sector , particularly for biotech and pharmaceutical companies. One of Duley's longtime clients is SciClone Pharmaceuticals Inc., which he advised on a licensing deal with Soligenix Inc. to develop, promote and market an oral mucositis treatment in ...

    Comment?

  2. Edge Therapeutics (EDGE) and The Medicines (MDCO) Head-To-Head ContrastRead the original story w/Photo

    Aug 1, 2018 | IntersportsWire

    ... risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. Receive ...

    Comment?

  3. Positive Media Coverage Somewhat Unlikely to Affect SciClone Pharmaceuticals (SCLN) Stock PriceRead the original story w/Photo

    May 27, 2018 | Daily Political

    Headlines about SciClone Pharmaceuticals have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time.

    Comment?

  4. The Medicines (MDCO) versus Its Peers Head to Head ContrastRead the original story w/Photo

    May 25, 2018 | IntersportsWire

    ... risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. Receive ...

    Comment?

  5. The Medicines (MDCO) & Its Rivals Head-To-Head ComparisonRead the original story w/Photo

    May 22, 2018 | AmericanBankingNews.com

    ... risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. Receive ...

    Comment?

  6. Critical Review: Medicines (MDCO) & Its CompetitorsRead the original story w/Photo

    May 13, 2018 | IntersportsWire

    ... risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. Receive ...

    Comment?

  7. Financial Review: Medicines (MDCO) vs. Its PeersRead the original story w/Photo

    May 10, 2018 | Daily Political

    ... risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. Receive ...

    Comment?

  8. Medicines (MDCO) vs. Its Peers Critical AnalysisRead the original story w/Photo

    May 8, 2018 | IntersportsWire

    ... risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. Receive ...

    Comment?

  9. Head-To-Head Review: Medicines (MDCO) & Its RivalsRead the original story w/Photo

    May 5, 2018 | AmericanBankingNews.com

    ... risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. Receive ...

    Comment?

  10. Aegerion Pharmaceuticals (AEGR) vs. SciClone Pharmaceuticals (SCLN) Head to Head SurveyRead the original story w/Photo

    Apr 1, 2018 | Daily Political

    Aegerion Pharmaceuticals and SciClone Pharmaceuticals are both small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends. 84.9% of Aegerion Pharmaceuticals shares are owned by institutional investors.

    Comment?

  11. SciClone Pharmaceuticals (SCLN) & CoLucid Pharmaceuticals (CLCD) Financial ContrastRead the original story w/Photo

    Feb 21, 2018 | AmericanBankingNews.com

    SciClone Pharmaceuticals and CoLucid Pharmaceuticals are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. This is a breakdown of current recommendations and price targets for SciClone Pharmaceuticals and CoLucid Pharmaceuticals, as provided by MarketBeat.com.

    Comment?

  12. Head-To-Head Survey: SciClone PharmaceuticalsRead the original story w/Photo

    Feb 19, 2018 | AmericanBankingNews.com

    SciClone Pharmaceuticals and Teligent are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings. SciClone Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 25.56%.

    Comment?

  13. SciClone Pharmaceuticals, Inc. (SCLN) Position Boosted by California...Read the original story w/Photo

    Jan 24, 2018 | IntersportsWire

    Complete the form below to receive the latest headlines and analysts' recommendationsfor SciClone Pharmaceuticals with our free daily email newsletter: California Public Employees Retirement System increased its stake in SciClone Pharmaceuticals, Inc. by 20.2% during the third quarter, HoldingsChannel.com reports. The fund owned 100,634 shares of the specialty pharmaceutical company's stock after buying an additional 16,934 shares during the period.

    Comment?

  14. Mckinley Carter Wealth Services Has Decreased Its Stake in J & J...Read the original story

    Jan 20, 2018 | Hill Country Times

    ... Inc, which manages about $1.30B and $867.10 million US Long portfolio, decreased its stake in Sciclone Pharmaceuticals Incco (NASDAQ:SCLN) by 35,000 shares to 67,261 shares, valued at $753,000 in 2017Q3, according to the filing. It also reduced its ...

    Comment?

  15. SciClone Pharmaceuticals (SCLN) Given Media Sentiment Rating of 0.25Read the original story w/Photo

    Jan 7, 2018 | IntersportsWire

    Media headlines about SciClone Pharmaceuticals have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time.

    Comment?

  16. Public Employees Retirement System of Ohio Invests $2.48 Million in...Read the original story w/Photo

    Jan 1, 2018 | IntersportsWire

    Complete the form below to receive the latest headlines and analysts' recommendationsfor SciClone Pharmaceuticals with our free daily email newsletter: Public Employees Retirement System of Ohio purchased a new position in shares of SciClone Pharmaceuticals, Inc. in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 221,421 shares of the specialty pharmaceutical company's stock, valued at approximately $2,480,000.

    Comment?

  17. SciClone Pharmaceuticals, Inc. (SCLN) Stake Lessened by Bank of New York Mellon CorpRead the original story w/Photo

    Dec 27, 2017 | IntersportsWire

    Bank of New York Mellon Corp reduced its stake in shares of SciClone Pharmaceuticals, Inc. by 0.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 798,073 shares of the specialty pharmaceutical company's stock after selling 5,311 shares during the quarter.

    Comment?

  18. SciClone Pharmaceuticals, Inc. (SCLN) Shares Sold by Allianz Asset Management GmbHRead the original story w/Photo

    Dec 24, 2017 | Daily Political

    Allianz Asset Management GmbH cut its position in SciClone Pharmaceuticals, Inc. by 12.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 232,872 shares of the specialty pharmaceutical company's stock after selling 34,020 shares during the quarter.

    Comment?

  19. Reviewing Sophiris BioRead the original story w/Photo

    Dec 24, 2017 | Daily Political

    Sophiris Bio and SciClone Pharmaceuticals are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. 5.5% of Sophiris Bio shares are owned by institutional investors.

    Comment?

  20. GSA Capital Partners LLP Sells 56,613 Shares of SciClone Pharmaceuticals, Inc.Read the original story w/Photo

    Dec 22, 2017 | IntersportsWire

    GSA Capital Partners LLP reduced its position in SciClone Pharmaceuticals, Inc. by 33.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 110,500 shares of the specialty pharmaceutical company's stock after selling 56,613 shares during the quarter.

    Comment?